INDICATIONS AND USAGE
Zarontin is indicated for the control of absence (petit mal) epilepsy.
Did you find an answer to your question?
Yes
No
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our medical information is accurate, up to date, and scientifically balanced.
ZARONTIN® Capsules (ethosuximide)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our medical information is accurate, up to date, and scientifically balanced.
ZARONTIN® Capsules Quick Finder
Dosage and Administration
DOSAGE AND ADMINISTRATION
Zarontin is administered by the oral route. The initial dose for patients 3 to 6 years of age is one capsule (250 mg) per day; for patients 6 years of age and older, 2...
Did you find an answer to your question?
Yes
No
Contraindications
CONTRAINDICATION
Ethosuximide should not be used in patients with a history of hypersensitivity to succinimides.
Did you find an answer to your question?
Yes
No
Warnings and Precautions
WARNINGS
Blood Dyscrasias
Blood dyscrasias, including some with fatal outcome, have been reported to be associated with the use of ethosuximide; therefore, periodic...
Did you find an answer to your question?
Yes
No
Adverse Reactions
ADVERSE REACTIONS
Body As A Whole: Allergic reaction, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Gastrointestinal System: Gastrointestinal symptoms...
Did you find an answer to your question?
Yes
No
Overdosage
OVERDOSAGE
Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. A relationship between ethosuximide toxicity and its plasma levels has not been established. The...
Did you find an answer to your question?
Yes
No
Description
DESCRIPTION
Zarontin (ethosuximide) is an anticonvulsant succinimide, chemically designated as alpha-ethyl-alpha-methyl-succinimide, with the following structural formula:
...
Did you find an answer to your question?
Yes
No
Clinical Pharmacology
CLINICAL PHARMACOLOGY
Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of...
Did you find an answer to your question?
Yes
No
How Supplied/Storage and Handling
HOW SUPPLIED
Zarontin is supplied as:
NDC 0071-0237-24: Bottles of 100. Each capsule contains 250 mg ethosuximide.
...
Did you find an answer to your question?
Yes
No
Medication Guide
MEDICATION GUIDE
MEDICATION GUIDE
ZARONTIN, (Ză rŏn' tĭn)
(ethosuximide)
Capsules, Oral Solution
Read this Medication Guide before you start taking ZARONTIN and each time you get a refill. There may be new...
Did you find an answer to your question?
Yes
No
Did you find an answer to your question?
Yes
No
Didn’t find what you were looking for? Contact us.
To interact with the Medical Information Digital Assistant click here.
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Report Adverse Event
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at(800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatchor by calling
(800)-332-1088.
(800)-332-1088.